Altimmune, Inc. develops pemvidutide, a late clinical-stage dual-action therapy targeting glucagon and GLP-1 receptors for serious liver diseases. Company news centers on pemvidutide development in metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), including clinical trial updates and FDA designations such as Fast Track and Breakthrough Therapy Designation where granted.
Altimmune updates also cover financial results, business updates, investor conference participation and capital actions used to fund development activity. Recurring financing news includes public offerings, registered direct offerings, common stock, pre-funded warrants and common stock warrants.
Altimmune (ALT) presented Phase 2 RECLAIM results showing pemvidutide reduced heavy drinking days in adults with moderate-to-severe alcohol use disorder. At Week 24, the primary endpoint was met: heavy drinking days per week fell by 4.20 days versus 2.75 with placebo (p=0.0014). Zero heavy drinking days were achieved by 42.2% versus 17.4%, while abstinent days increased to 38.9% versus 20.5%. Weight and liver-health measures also improved.
Adverse events were primarily mild-to-moderate, but gastrointestinal events were more frequent with pemvidutide. Treatment discontinuation was 20% versus 22% with placebo. Altimmune has an FDA End-of-Phase 2 meeting scheduled in December on its Phase 3 program design for alcohol use disorder. Separate 48-week IMPACT Phase 2b analyses in metabolic dysfunction-associated steatohepatitis showed improvements in liver measures versus placebo, with no severe gastrointestinal treatment-emergent adverse events.
Altimmune (ALT) will present RECLAIM Phase 2 results for pemvidutide in alcohol use disorder at The Liver Meeting on November 9, 2026.
The late-breaking oral presentation covers adults with moderate-to-severe alcohol use disorder. The randomized, double-blind, placebo-controlled trial compared once-weekly pemvidutide 2.4 mg with placebo over 24 weeks. Topline results announced in July 2026 showed a statistically significant reduction in heavy drinking days per week versus placebo, meeting the primary endpoint. The trial also met key secondary endpoints, including reduced World Health Organization Risk Drinking Levels and zero heavy drinking days. Altimmune described tolerability as generally favorable.
An End-of-Phase 2 FDA meeting is scheduled for December to discuss the Phase 3 registrational program for pemvidutide in alcohol use disorder.
Altimmune (Nasdaq: ALT) will report its third quarter 2026 financial results and provide a business update on November 12, 2026. Management will host a conference call at 8:30 a.m. ET that day. A live webcast will be available on the company’s Investor Relations website, with a replay available shortly afterward for up to three months.
Altimmune (Nasdaq: ALT) appointed Peter Greenleaf and Alex Howarth to its board of directors, effective November 2, 2026. As part of the planned transition, John M. Gill, Mitchel Sayare and Klaus O. Schafer will retire and not seek reelection when their current one-year terms end at the 2027 Annual Meeting.
The company links the board changes to its transition toward late-stage development of pemvidutide, an investigational treatment for serious liver diseases. Its Phase 3 MASH trial is funded and ongoing. Greenleaf most recently served as CEO of Aurinia Pharmaceuticals, where he guided its transition from development to commercialization. Howarth most recently served as CFO of Madrigal Pharmaceuticals, helping its transition into a commercial organization that launched the first approved treatment for MASH.
Altimmune (Nasdaq: ALT) will present new pemvidutide clinical and preclinical data at AASLD’s The Liver Meeting on November 5–9, 2026.
In 48-week analyses of the IMPACT Phase 2b study in metabolic dysfunction-associated steatohepatitis (MASH), pemvidutide reduced liver stiffness and ELF score, two non-invasive markers of scarring, alongside liver fat and alanine aminotransferase compared with placebo. Gastrointestinal adverse events were mild to moderate, with none severe. Discontinuations due to adverse events were lower than with placebo, and more pemvidutide-treated patients completed treatment despite no dose titration. Preclinical results showed reduced mean alcohol intake in a hamster model. The company’s PERFORMA Phase 3 MASH trial is actively enrolling.
Altimmune (ALT) will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.
The company, which is developing pemvidutide for serious liver diseases, will provide live access via a webcast in the Events section of its website.
Altimmune (ALT) will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, at 9:30 a.m. ET.
The late clinical-stage biopharmaceutical company is developing pemvidutide for serious liver diseases, and will provide webcast access to the session via the Events section of its website.
Altimmune (Nasdaq: ALT) reported second quarter 2026 results and a business update, highlighting advancement of its lead candidate pemvidutide in serious liver diseases. The company ended June 30, 2026 with $519 million in cash, cash equivalents and investments, supported by a completed $225 million public offering in April.
Altimmune initiated the global PERFORMA Phase 3 MASH trial, after pemvidutide received FDA Breakthrough Therapy and Fast Track designations for MASH. In AUD, the RECLAIM Phase 2 trial met its primary endpoint with a statistically significant reduction in heavy drinking days and achieved key FDA‑recognized secondary endpoints, with a generally favorable safety profile. In ALD, the company fully enrolled the RESTORE Phase 2 trial and amended the protocol to more fully assess liver benefits, with topline data expected in the second half of 2027.
For Q2 2026, Altimmune recorded R&D expenses of $18.7 million, G&A expenses of $7.6 million, and a net loss of $22.8 million, or $0.12 per share, compared with a $22.1 million net loss, or $0.27 per share, in Q2 2025.
Altimmune (Nasdaq: ALT) will report its second quarter 2026 financial results on Wednesday, August 12, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to review results and provide a business update, with live access and a replay available via the company’s Investor Relations website.
Altimmune (Nasdaq: ALT) has begun enrolling patients in PERFORMA, a global, randomized, double-blind, placebo-controlled Phase 3 trial of investigational drug pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis.
PERFORMA is Altimmune’s registrational study in MASH, designed to evaluate fibrosis improvement, MASH resolution and clinical outcomes, with a 52-week data readout anticipated in 2029. The trial follows the IMPACT Phase 2b study, where pemvidutide showed statistically significant MASH resolution, improvements in non-invasive measures of fibrosis and liver health, meaningful weight loss, and a generally favorable tolerability profile. Pemvidutide, a balanced glucagon/GLP-1 dual receptor agonist, is also in development for alcohol use disorder and alcohol-associated liver disease. According to Altimmune, the study design incorporates feedback from the U.S. FDA and European regulators, and pemvidutide has received FDA Fast Track and Breakthrough Therapy designations for MASH.